title: FKBP51 and the NF-κB regulatory pathway in cancer.
abstract: Constitutive activation of NF-κB occurs in a significant percentage of human cancers. Genetic abnormalities of tumors often enhance normal NF-κB signaling. Chronic inflammation is also associated with constitutive NF-κB activation and increases the risk of cancer. Aberrant NF-κB activation favors cellular transformation, sustains cancer survival, and contributes to tumor invasion. Strategies to inhibit NF-κB represent a promising therapeutic option against cancer. In the last decade, several studies point to the large immunophilin FKBP51 as an important element for the control of NF-κB activation in human neoplasia. This article is an overview of the causes of aberrant NF-κB regulation in cancer and highlights recent papers that implicate FKBP51 in such deregulation.
authors.affiliation: Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Via Pansini, 5, 80131 Naples, Italy. romanos@dbbm.unina.it
authors.forename: Simona
authors.initials: S
authors.lastname: Romano
authors.forename: Massimo
authors.initials: M
authors.lastname: Mallardo
authors.forename: Maria Fiammetta
authors.initials: MF
authors.lastname: Romano
mesh_terms: D000818:Animals; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000235:genetics / Q000473:pathology*; D015398:Signal Transduction; D022021:Tacrolimus Binding Proteins / Q000378:metabolism*; D000099159:Tacrolimus Binding Protein 5
chemical_list: D016328:NF-kappa B; D022021:Tacrolimus Binding Proteins; D000099159:Tacrolimus Binding Protein 5